New Risk Scoring System for Predicting Acute Exacerbation of Interstitial Pneumonia after Chemotherapy for Lung Cancer Associated with Interstitial Pneumonia

Lung cancer is strongly associated with interstitial pneumonia (IP) [1 –4]. IP is considered to be a risk factor for lung carcinogenesis [1,5]. Acute exacerbation (AE) refers to an episode of acute respiratory worsening without an identifiable cause. AE develops during the course of IP in about 5% to 15% of affected patients and can occur at any time during the clini cal course of IP [6–8]. AE can lead to death within a period of a few weeks to a few months [7,8]. However, it can be difficult to distinguish AE of IP from chemotherapy-related lung injury on the basis of clinical findings, such as CT images, and laboratory results.

Source: Lung Cancer - October 7, 2018 Category: Cancer & Oncology Authors: Kazutoshi Isobe, Kyohei Kaburaki, Hiroshi Kobayashi, Go Sano, Susumu Sakamoto, Yujiro Takai, Takashi Makino, Naobumi Tochigi, Akira Iyoda, Sakae Homma Source Type: research